Formulation, Optimization, and Evaluation of Liposomal Amphotericin B for Improved Antifungal Therapy
Background: Amphotericin B (AmB) remains a first-line therapeutic agent due to its broad-spectrum fungicidal activity and low microbial resistance. However, conventional formulations are severely restricted by dose-limiting nephrotoxicity driven by drug self-aggregation. Nanotechnology-driven drug delivery systems, par...